Tysabri(natalizumab)
Tyruko, Tysabri (natalizumab) is an antibody pharmaceutical. Natalizumab was first approved as Tysabri on 2004-11-23. It is used to treat crohn disease and multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis and relapsing-remitting multiple sclerosis. The pharmaceutical is active against integrin alpha-4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Tyruko, Tysabri
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tysabri | Biologic Licensing Application | 2024-10-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple sclerosis | EFO_0003885 | D009103 | G35 |
| crohn disease | EFO_0000384 | D003424 | K50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2323 | Injection, natalizumab, 1 mg |
Clinical
Clinical Trials
148 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 4 | 12 | 14 | 26 | 70 | 124 |
| Sclerosis | D012598 | — | — | 4 | 10 | 14 | 23 | 60 | 109 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 2 | 5 | 11 | 13 | 28 | 59 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | 3 | 2 | 2 | 9 |
| Leukoencephalopathies | D056784 | HP_0002352 | — | — | — | — | 1 | 4 | 5 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | 1 | 4 | 5 |
| Sleepiness | D000077260 | — | R40.0 | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
| Immune reconstitution inflammatory syndrome | D054019 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | 1 | 2 | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 2 | — | — | — | 2 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 2 | — | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | — | 2 | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | — | — | 2 |
| Cerebral infarction | D002544 | — | I63 | — | 2 | — | — | — | 2 |
| Graft vs host disease | D006086 | — | D89.81 | — | 2 | — | — | — | 2 |
| Demyelinating diseases | D003711 | — | — | — | 1 | — | — | 1 | 2 |
| Osteosarcoma | D012516 | — | — | 1 | 1 | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | 1 | — | — | — | — | 1 |
| Inclusion body myositis | D018979 | EFO_0007323 | G72.41 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 3 | 3 |
| Atrophy | D001284 | — | — | — | — | — | — | 2 | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 1 | 1 |
| Squamous intraepithelial lesions | D000081483 | — | — | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 1 | 1 |
| Nerve degeneration | D009410 | HP_0002180 | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Aggression | D000374 | EFO_0003015 | — | — | — | — | — | 1 | 1 |
| Prenatal exposure delayed effects | D011297 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Natalizumab |
| INN | natalizumab |
| Description | Immunoglobulin G 4 (human-mouse monoclonal AN1002264-chain anti-human integrin 4), disulfide with human-mouse monoclonal AN100226 light chain, dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6FG1:A|HEAVY CHAIN OF FAB NAA32
QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYTMHWVRQAPGQRLEWMGWINAGHGTTKYSQKFQGRVTITRDTSASTAY
MELSSLRSEDTAVYYCARPTSEGVAGPSRYYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTENLYF
Q
>6FG1:D|LIGHT CHAIN OF FAB NAA32
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQS
EDFAVYYCQQYNNWPPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHEGLSSPVTKSFNRGEC
>6FG1:H|HEAVY CHAIN OF FAB NATALIZUMAB
QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAY
MELSSLRSEDEAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPENLYFQ
>6FG1:L|LIGHT CHAIN OF FAB NATALIZUMAB
DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQP
EDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 4IRZ, 6FG1, 6FG2 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201607 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00108 |
| UNII ID | 3JB47N2Q2P (ChemIDplus, GSRS) |
Target
Agency Approved
ITGA4
ITGA4
Organism
Homo sapiens
Gene name
ITGA4
Gene synonyms
CD49D
NCBI Gene ID
Protein name
integrin alpha-4
Protein synonyms
269C wild type, alpha 4 subunit of VLA-4 receptor, antigen CD49D, alpha-4 subunit of VLA-4 receptor, CD49 antigen-like family member D, CD49d, Integrin alpha-IV, very late activation protein 4 receptor, alpha 4 subunit, VLA-4 subunit alpha
Uniprot ID
Mouse ortholog
Itga4 (16401)
integrin alpha-4 (Q00651)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tysabri – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tysabri – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,093 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tysabri
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
203,204 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use